Cargando…
Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes?
Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685630/ https://www.ncbi.nlm.nih.gov/pubmed/33248018 http://dx.doi.org/10.1016/j.cmet.2020.11.015 |
| _version_ | 1783613214002511872 |
|---|---|
| author | Donath, Marc Y. |
| author_facet | Donath, Marc Y. |
| author_sort | Donath, Marc Y. |
| collection | PubMed |
| description | Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes. |
| format | Online Article Text |
| id | pubmed-7685630 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76856302020-11-25 Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? Donath, Marc Y. Cell Metab Preview Patients with a metabolic syndrome (overweight, diabetes, hypertension, and dyslipidemia) have a particularly bad outcome if infected with SARS-CoV-2. Yu et al. (2020) suggest that insulin therapy itself may promote fatality in patients with COVID-19 and diabetes. Elsevier Inc. 2021-01-05 2020-11-24 /pmc/articles/PMC7685630/ /pubmed/33248018 http://dx.doi.org/10.1016/j.cmet.2020.11.015 Text en © 2020 Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Preview Donath, Marc Y. Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? |
| title | Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? |
| title_full | Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? |
| title_fullStr | Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? |
| title_full_unstemmed | Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? |
| title_short | Glucose or Insulin, Which Is the Culprit in Patients with COVID-19 and Diabetes? |
| title_sort | glucose or insulin, which is the culprit in patients with covid-19 and diabetes? |
| topic | Preview |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7685630/ https://www.ncbi.nlm.nih.gov/pubmed/33248018 http://dx.doi.org/10.1016/j.cmet.2020.11.015 |
| work_keys_str_mv | AT donathmarcy glucoseorinsulinwhichistheculpritinpatientswithcovid19anddiabetes |